CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,820 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04393974
NCT04393974N/ACompleted
CompareCT.gov

OnCovid: Natural History and Outcomes of Cancer Patients During the COVID19 Epidemic

Imperial College London·observational·Posted May 19, 2020·Updated Feb 17, 2026

In Brief

An observational study for Cancer and Sars-CoV2. Completed, enrolled 3,820 participants across 25 sites in 6 countries.

Detailed Summary

Routinely collected data will be used to assess the morbidity and mortality of cancer patients following a positive COVID-19 infection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Sars-CoV2
CountriesBelgium, France, Germany, Italy, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 19, 2020
Enrollment StartApr 1, 2020
Primary CompletionApr 1, 2024
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 6.1 years ago